Australian UDI requirements have commenced: what sponsors and manufacturers should check

What has changed?

The Australian UDI system introduces standardised identifiers for medical devices and a national database for device information. Its purpose is to improve traceability, support safety action and make accurate device information easier to access across the product lifecycle.

The rollout is staged. From 1 July 2026, the first mandatory requirements apply to certain Class IIb and Class III devices supplied in Australia. Lower-risk devices and IVDs are expected to enter the framework over later phases, so businesses should confirm the date and rules that apply to each device rather than relying on a portfolio-wide assumption.

Why this is more than a labelling project

A UDI appears on device labels or packaging in a prescribed form, but compliance also depends on the accuracy and ongoing maintenance of the associated data. Manufacturers and sponsors may need to align product master data, packaging controls, change procedures and regulatory records.

The Australian sponsor should understand how the manufacturer assigns identifiers, who owns the source data, how records will be submitted to AusUDID and how changes will be communicated. Those arrangements are particularly important when a sponsor represents several overseas manufacturers or a manufacturer supplies multiple device families.

A practical readiness review

A focused review should begin with the ARTG entries and product configurations actually supplied in Australia. From there, map the responsible legal manufacturer, device class, applicable compliance date, identifier status and AusUDID record owner.

• Confirm the classification and applicable UDI compliance date for each device family.
• Review labels, packaging levels and direct-marking questions where relevant.
• Check that identifiers and data fields match controlled product information.
• Define who submits, verifies and maintains AusUDID records.
• Update quality-system procedures for new devices, corrections and lifecycle changes.
• Document any exemption, transition or consent-to-supply position relied upon.

What should happen next?

Organisations already supplying Class IIb or Class III devices should treat unresolved gaps as an active compliance issue. For products in development or awaiting ARTG inclusion, UDI should be built into the Australian market-entry plan rather than added after approval.

The precise requirements depend on the device, supply status and circumstances. Use current TGA guidance and obtain product-specific advice before making a regulatory decision.